Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxil followed by Bexarotene in Advanced CTCL
NCT00255801Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2005
- Primary completion
- Oct 2017
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of doxorubicin, bexarotene in cutaneous T-cell lymphoma (CTCL), sponsored by Memorial Sloan Kettering Cancer Center. Started Nov 2005; status: completed.
02
Drugs
doxorubicinbexarotene
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT00255801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00255801.